2. UroToday Home
  3. Conference Highlights
  4. ASCO GU 2018

ASCO GU 2018 Press

Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer Announced at 2018 ASCO Genitourinary Cancers Symposium

Truckee, CA (UroToday.com) Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage biotechnology company developing cancer therapeutics, announced efficacy and safety data from an ongoing Phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer (nmPC). Mack Roach III, M.D., FASTRO, FACR, University of California, San Francisco (UCSF), presented the data in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, Calif. 

Bayer to Feature Prostate Cancer Research at ASCO GU 2018 Symposium

Truckee, CA (UroToday.com) Bayer announced that research on radium Ra 223 dichloride injection and darolutamide, the company's investigational oral androgen receptor (AR) antagonist, in prostate cancer will be presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 8-10 in San Francisco.

Apalutamide Delays Prostate Cancer Metastases by More Than Two Years

Truckee, CA (UroToday.com)  Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk for developing metastatic disease, and for whom no approved treatments exist. Men who received apalutamide had a 72% lower risk of metastasis or death than those who received placebo. 

New Model Predicts Survival for People with Bladder Cancer Receiving Immunotherapy

Truckee, CA (UroToday.com)  Researchers have developed a model to predict overall survival for people with advanced urothelial cancers treated with the immune checkpoint inhibitor atezolizumab. The model, which is based on six clinical factors, may help inform treatment decisions for use of atezolizumab in these patients. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.

Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer, with Fewer Side Effects

Truckee, CA (UroToday.com)  In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth by about three months longer than sunitinib, another targeted therapy. The benefit of atezolizumab plus bevacizumab was greater for patients with PD-L1-positive tumors. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.

Chemotherapy Added to Hormone Therapy for Prostate Cancer Improves Quality of Life

Truckee, CA (UroToday.com) A new analysis of the ongoing STAMPEDE clinical trial found that adding the chemotherapy drug docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Docetaxel was also found to be cost-effective. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.

The 2018 Genitourinary Cancers Symposium (ASCO GU 2018) will Feature Insights for Management of Prostate, Bladder and Kidney Cancers

Truckee, CA. (UroToday.com) – The 2018 Genitourinary Cancers Symposium will take place February 8-10, 2018  in San Francisco, California. Presentations at the Symposium will discuss the latest strategies in the prevention, screening, diagnosis, and treatment of prostate, kidney, testicular, and bladder cancers. UroToday/GU OncToday will be providing exensive coverge of the conference.